Literature DB >> 10567903

Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay.

P O Chappuis1, A Estreicher, B Dieterich, H Bonnefoi, M Otter, A P Sappino, R Iggo.   

Abstract

p53 status was tested in 180 patients with primary breast cancer using a yeast functional assay. Mutations were identified in 32% of cases. Only half were point missense mutations; the remainder were nonsense, insertion, deletion and splice site mutations. Twenty-two percent of mutations were located outside exons 5-8. For a median follow-up of 88 months, survival analysis showed that p53 mutation conferred a worse prognosis in the whole population and the node-positive subgroup but not in node-negative patients. p53 status, tumour size >2 cm, axillary lymph node metastasis and high histological grade were major adverse risk factors in univariate analysis. Multivariate analysis of 153 patients for whom full data were available showed that p53 status contributed prognostic information when tumour size and lymph node status were taken into account but not when histological grade was included. p53 status thus contributes only limited new prognostic information in breast cancer when established prognostic factors are taken into account. Int. J. Cancer (Pred. Oncol.) 84:587-593, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10567903     DOI: 10.1002/(sici)1097-0215(19991222)84:6<587::aid-ijc8>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Authors:  Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo
Journal:  Lancet Oncol       Date:  2011-05-11       Impact factor: 41.316

2.  Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.

Authors:  P M Duddy; A M Hanby; D M Barnes; R S Camplejohn
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

3.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

4.  Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.

Authors:  Xiao-mo Wu; Jing-geng Fu; Wang-zhong Ge; Jiang-yan Zhu; Jun-yong Wang; Wei Zhang; Wei Qian; Ke-ke Huo
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

Review 5.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

6.  Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.

Authors:  Joshua Merritt; Kim G Roberts; James A Butz; Jeremy S Edwards
Journal:  Genomic Med       Date:  2007-09-05

7.  Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.

Authors:  A Kulić; M Sirotković-Skerlev; S Jelisavac-Cosić; D Herceg; Z Kovac; D Vrbanec
Journal:  Med Oncol       Date:  2009-09-11       Impact factor: 3.064

8.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

9.  Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.

Authors:  Alberto Inga; Francesca Storici; Thomas A Darden; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

10.  An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers.

Authors:  E M Pinto; R C Ribeiro; J Li; L Taja-Chayeb; L F Carrasco; M de Lourdes Peña-Torres; S Vidal-Millán; H Maldonado-Mtz; A Dueñas-González; L McGregor; G P Zambetti
Journal:  Oncogenesis       Date:  2012-02-20       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.